## Improving business traction bodes well...

A healthy revival in credit offtake, especially individual segment thereby leading to improvement in operational performance remained a key highlight of the quarter. Asset quality remained broadly resilient.
For Q4FY21, the company posted a healthy operational performance with NII growth of $10 \%$ YoY to ₹ 3918 crore, driven by margin expansion and healthy AUM growth. Reported NIM was at $3.5 \%$, up $\sim 10$ bps OoO, YoY. Expansion in NIMs was aided by 8 bps sequential uptick in non-individual spreads. Reducing levels of surplus liquidity also helped in NIM expansion. Other income growth came in at ₹ 1224 crore, up $62 \%$ YoY. The sharp rise was partly on account of dividend income. The bank has made provisions worth ₹ 719 crore during the quarter including Covid-19 provisions, taking cumulative Covid related provisions at ₹ 844 crore. PAT for the quarter was at ₹ 3180 crore; higher than our estimates.
Asset quality was largely steady on a proforma basis but reported GNPA showed 31 bps uptick to $1.98 \%$ as standstill asset classification norms are quashed. On a proforma basis, GNPA ratio was broadly stable at $1.98 \%$ vs. $1.91 \%$ OoO. GNPA in individual and non-individual book were at $0.99 \%$ and $4.77 \%$ versus proforma levels of $0.98 \%$ and $4.35 \%$ OoQ, respectively. Collection efficiency in individual loans improved to $98 \%$ vs. $97.6 \%$ in the previous quarter. The quantum of loans restructured under RBl's resolution framework for Covid-19 related stress was at 0.8\% of AUM, of which $27 \%$ are individual loans while $73 \%$ come from non-individual book. One large single account under resolution framework amounted to $0.5 \%$ of AUM. Provisioning buffer was at a healthy $\sim \mathbf{2 . 6 2 \%}$ of advances vs. $\sim \mathbf{2 . 8} \%$ of stressed asset ( $1.98 \%$ proforma GNPA $+0.8 \%$ restructuring).
AUM growth trajectory improved to $10.3 \%$ YoY and $3.2 \%$ OoQ to ₹ 569894 crore. Healthy AUM growth was driven by $13.2 \%$ growth in individual portfolio led by strong demand for home amid lower interest rates, softer property prices and concessional stamp duty in certain states. Among nonindividual book, corporate segment (comprising 6\% of AUM) and LRD (7\% of AUM) witnessed a pick-up in Q4FY21, after a dip in 9MFY21. However, the company remained cautious on construction finance segment $(10 \%$ of AUM) and continued to gradually de-grow the book in the last fiscal. Affordable segment continued to stay in focus with $33 \%$ by volume, $16 \%$ by value disbursements. After adding back loans sold, growth in individual book was at $19 \%$ YoY while growth in total loan book was at $15 \%$ YoY.

## Valuation \& Outlook

Robust pick up in individual disbursement at $60 \%$, margin expansion of $\sim 10$ bps and collection efficiency at $98 \%$ reflect healthy revival in individual business which comprises $\sim 74 \%$ of gross loan book. We remain positive on earnings visibility given 1) business growth led by market leadership, 2) adequate capital of $22.2 \%, 3$ ) funding advantage and 4) healthy provision buffer. Healthy performance in subsidiaries would aid consolidated earnings. Stake sale in HDFC Ergo (to reduce stake as per regulatory regime) could lead to one off inflows. We expect earnings to grow at 14.6\% CAGR in FY21-23E with healthy RoA at $\sim 2.2 \%$ in FY23E. We maintain our target price at ₹ 3100 , valuing core business at $2.5 x$ FY23E ABV and subsidiaries at $15 \%$ holding company discount. We maintain BUY.

| Key Financial Summary | FY19 | FY20 | FY21 | FY22E | FY23E |
| :--- | ---: | ---: | ---: | ---: | ---: |
| ₹ crore | 11,624 | 12,941 | 14,157 | 16,485 | 19,524 |
| NII | 14,054 | 26,264 | 17,763 | 20,476 | 23,683 |
| PPP | 9,632 | 17,770 | 12,027 | 13,645 | 15,818 |
| PAT | 449.4 | 497.4 | 602.1 | 632.5 | 665.1 |
| ABV (₹) | 44.6 | 24.3 | 41.7 | 33.0 | 28.5 |
| P/E | 5.6 | 5.0 | 4.1 | 3.9 | 3.8 |
| P/ABV | 2.2 | 3.6 | 2.0 | 2.3 | 2.3 |
| RoA | 14.4 | 21.7 | 11.1 | 12.3 | 13.5 |
| RoE |  |  |  |  |  |

## GHDFC

WITH YOU, RIGHT THROUGH

| Particulars |  |
| :--- | ---: |
| Particulars | Amount |
| Market Capitalisation | $₹ 450310$ crore |
| GNPA (04FY21) | $₹ 9608$ crore |
| NIM (04FY21) (reported) | 3.50 |
| 52 week H/L | $2895 / 1486$ |
| Networth | $₹ 108616$ crore |
| Face value | $₹ 2$ |
| DII Holding (\%) | 16.1 |
| FIl Holding (\%) | 72.8 |

## Key Highlights

- $60 \%$ YoY growth in disbursements in individual segment
- Outstanding total provision at $2.6 \%$ of loans vs. $2.8 \%$ of stressed assets
- Maintain target price at $₹ 3100$ with BUY recommendation

Risk to our call

- Higher slippages from non-individual book could impact profitability
- Persistent impact of pandemic may delay further growth in business

Research Analyst
Kajal Gandhi
kajal.gandhi@icicisecurities.com
Vishal Narnolia
vishal.narnolia@icicisecurities.com
Sameer Sawant
Sameer.Sawant@icicisecurities.com

| Exhibit 1: Variance Analysis |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 04FY21 | 04FY21E | 04FY20 | YoY (\%) | $03 F Y 21$ | O00 (\%) | Comments |
| NII | 3,918 | 3,828 | 3,564 | 9.9 | 3,941 | -0.6 | NII growth driven by margin expansion \& healthy AUM growth |
| Reported NIM (\%) | 3.5 | 3.2 | 3.4 | 10 bps | 3.4 | 10 bps | NIMs expanded as excess liquidity reduced |
| Other Income | 1,224 | 737 | 756 | 61.9 | 1,006 | 21.6 | Other income jumped due to dividend income effect on YoY basis |
| Net Total Income | 5,142 | 4,565 | 4,320 | 19.0 | 4,947 | 3.9 |  |
| Staff cost | 138 | 149 | 140 | -1.3 | 291 | -52.6 |  |
| Other Operating Expenses | 361 | 476 | 214 | 68.8 | 310 | 16.4 |  |
| PPP | 4,643 | 3,940 | 3,966 | 17.1 | 4,347 | 6.8 |  |
| Provision | 719 | 380 | 1,274 | -43.6 | 594 | 21.0 | Buffer creation led to sequential hike in provision |
| PBT | 3,924 | 3,560 | 2,692 | 45.7 | 3,753 | 4.6 |  |
| Tax Outgo | 744 | $819{ }^{\circ}$ | 460 | $61.8{ }^{\text {r }}$ | 827 | -10.0 |  |
| PAT | 3,180 | 2,741 | 2,233 | 42.4 | 2,926 | 8.7 | Higher other income and controlled opex helped PAT ahead of estimates |

## Key Metrics

| GNPA | 9,609 | 8,112 | 8,755 | 9.8 | 7,876 | 22.0 | Spike in reported GNPA but on proforma basis asset quality was <br> largely stable |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | :--- |
| Loans | 498,298 | 504,992 | 450,903 | 10.5 | 483,919 | 3.0 | Led by $13 \%$ YoY growth in Individual loans |
| Borrowings | 441,365 | 459,952 | 419,102 | 5.3 | 433,917 | 1.7 |  |

Source: Company, ICICI Direct Research


Source: Company, ICICI Direct Research

| Exhibit 3: Assumption | Current |  |  |  |  |  | Earlier |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | FY20 | FY21 | FY22E | FY23E | FY21 | FY22E | FY23E |
| Credit growth (\%) | 8.2 | 10.3 | 13.7 | 13.4 | 10.0 | 13.3 | 13.4 |
| NIM Calculated (\%) | 2.7 | 2.7 | 2.9 | 3.0 | 2.9 | 3.0 | 3.0 |
| Cost to income ratio (\% | 5.4 | 9.2 | 8.6 | 8.1 | 8.9 | 7.8 | 7.4 |
| GNPA (₹ crore) | 8,706 | 9,782 | 10,033 | 10,587 | 11,898 | 12,146 | 12,695 |
| NNPA (₹ crore) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |

Source: Company, IC/C/ Direct Research

| Exhibit 4: SOTP valuation |  |  |  |  |  |  |  |  |  |
| :--- | :--- | ---: | ---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Business Segment | Basis of valuation | HDFC's stake (\%) | ₹/share |  |  |  |  |  |  |
| HDFC Ltd | 2.5x FY23E Core Mortgage ABV | 100 | 1,666 |  |  |  |  |  |  |
| HDFC Bank | 3.7x FY23E ABV | 19.4 | 1,000 |  |  |  |  |  |  |
| HDFC AMC | 12.4\% FY23E AUM | 52.7 | 186 |  |  |  |  |  |  |
| HDFC Life Insurance | 5x FY23E EV | 50.1 | 446 |  |  |  |  |  |  |
| HDFC ERGO | 18x FY23E PAT | 50.8 | 25 |  |  |  |  |  |  |
| Bandhan Bank | Market cap | 9.9 | 30 |  |  |  |  |  |  |
| Value per share |  |  | 3,354 |  |  |  |  |  |  |
| Discount @ 15\% |  |  | 253 |  |  |  |  |  |  |
| Value per share of HDFC |  |  | $\mathbf{3 , 1 0 0}$ |  |  |  |  |  |  |

Source: Company, ICICI Direct Research

Story in Charts
Exhibit 5: Individual book to drive growth


Source: Company, ICICI Direct Research
Exhibit 6: Individual segment continues to be key driver


Source: Company, ICICI Direct Research

## Exhibit 7: Incremental AUM contribution for FY21


$\square$ Individual Loans Non-individual

[^0]Exhibit 8: Borrowing profile


Source: Company, IC/CI Direct Research


Source: Company, ICICI Direct Research


Source: Company, ICICI Direct Research

| Exhibit 11: Expected credit loss (ECL) based on exposure at default (EAD) |  |  |  |
| :--- | :---: | :---: | :---: |
| As per IND AS | Mar-21 | Dec 20 | Mar 20 |
| Gross Stage 1 | $4,54,029$ | $4,37,507$ | $4,15,864$ |
| ECL Provision Stage 1 | 1,087 | 892 | 346 |
| Net Stage 1 | $4,52,942$ | $4,36,615$ | $4,15,518$ |
| Coverage Ratio\% Stage 1 | $0.2 \%$ | $0.2 \%$ | $0.1 \%$ |
| Gross Stage 2 | 31,547 | 34,208 | 24,794 |
| ECL Provision Stage 2 | 5,881 | 6,008 | 5,750 |
| Net Stage 2 | 25,666 | 28,200 | 19,044 |
| Coverage Ratio\% Stage 2 | $18.6 \%$ | $17.6 \%$ | $23.2 \%$ |
| Gross Stage 3 | 11,632 | 11,002 | 10,273 |
| ECL Provision Stage 3 | 6,057 | 5,442 | 4,892 |
| Net Stage 3 | 5,575 | 5,560 | 5,381 |
| Coverage Ratio\% Stage 3 | $52.1 \%$ | $49.5 \%$ | $47.6 \%$ |
| EAD | $4,97,208$ | $4,82,717$ | $4,50,931$ |
| ECL Provision | 13,025 | 12,342 | 10,988 |
| Net | $4,84,183$ | $4,70,375$ | $4,39,943$ |
| ECL/EAD | $2.6 \%$ | $2.6 \%$ | $2.4 \%$ |

Source: Company, IC/CI Direct Research

## Exhibit 12: Cost-to-income ratio to decline



Source: Company, ICICI Direct Research
Exhibit 13: Return ratio showing improving trajectory


Source: Company, ICICI Direct Research

Exhibit 14: Shareholding Pattern

| in \% | Mar-20 | Jun-20 | Sep-20 | Dec-20 | Mar-21 |
| :--- | ---: | ---: | ---: | ---: | ---: |
| Promoter | - | - | - | - | - |
| FII | 70.9 | 70.2 | 70.0 | 72.0 | 72.8 |
| DII | 17.8 | 18.3 | 18.5 | 17.1 | 16.1 |
| Others | 11.3 | 11.5 | 11.6 | 10.9 | 11.1 |

Source: Company, IC/C/ Direct Research


Source: Company, IC/CI Direct Research

Financial summary


| Exhibit 18: Balance sheet |  |  | ₹ crore |  |  | Exhibit 19: Growth ratios (\%) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Year-end March) | FY19 | FY20 | FY21 | FY22E | FY23E | (Year-end March) | FY19 | FY20 | FY21 | FY22E | FY23E |
| Sources of Funds |  |  |  |  |  | Total assets | 16.1 | 14.6 | 7.6 | 12.2 | 12.4 |
| Capital | 344.3 | 346.4 | 360.8 | 360.8 | 360.8 | Advances | 13.4 | 8.2 | 10.3 | 13.7 | 13.4 |
| Reserves and Surplus | 77011.2 | 85811.7 | 108255.5 | 113744.5 | 119620.4 | Borowings | 14.5 | 14.4 | 5.3 | 13.9 | 14.0 |
| Networth | 77355.5 | 86158.1 | 108616.3 | 114105.3 | 119981.2 | Total Income | 23.6 | 35.5 | -18.0 | 20.0 | 14.3 |
| Borrowings | 366214.4 | 419101.6 | 441365.0 | 502913.1 | 573104.6 | Net interest income | 20.6 | 11.3 | 9.4 | 16.4 | 18.4 |
|  |  |  |  |  |  | Operating expenses | -22.0 | 0.8 | 20.0 | 6.8 | 8.0 |
| Other Liabilities \& Provisions | 15207.1 | 18833.3 | 17559.2 | 19829.0 | 22443.7 | Operating profit (excl trading) | 50.8 | 105.6 | -21.8 | 40.6 | 37.1 |
| Total | 4,58,777 | 5,24,093 | 5,67,541 | 6,36,847 | 7,15,529 | Net profit | -12.1 | 84.5 | -39.3 | 26.5 | 15.9 |
| Applications of Funds |  |  |  |  |  | Book value | 37.4 | 11.4 | 26.1 | 5.1 | 5.1 |
| Fixed Assets | 972.0 | 1884.5 | 1827.0 | 2009.7 | 2210.7 | EPS | (14.4) | 83.3 | (41.7) | 26.5 | 15.9 |
| Investments | 47836.1 | 64944.4 | 68636.8 | 69874.2 | 74851.4 | Source: Company, ICICI Direct Research |  |  |  |  |  |
| Advances | 406607.1 | 439943.8 | 485296.0 | 551622.4 | 625691.7 |  |  |  |  |  |  |
| Other Assets | 3361.8 | 17320.4 | 11780.7 | 13341.0 | 12775.7 |  |  |  |  |  |  |
| Total | 4,58,777 | 5,24,093 | 5,67,541 | 6,36,847 | 7,15,529 |  |  |  |  |  |  |

[^1]Exhibit 20: ICICI Direct coverage universe (BFSI)

|  | CMP |  |  | M Cap |  |  |  |  | ( x ) |  |  | ( x ) |  |  | (\%) |  |  | (\%) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Sector / Company | (₹) | TP(₹) | Rating | (₹ bn) | FY21 | FY22E | FY23E | FY2 | FY22E | FY23E | FY21 | FY22E | FY23E | FY21 | FY22E | Y23E | FY2 |  | Y23E |
| LIC Housing Finance (LICHF) | 422 | 475 | Hold | 213 | 58.9 | 65.3 | 76.0 | 7.2 | 6.5 | 5.6 | 1.3 | 1.1 | 1.0 | 1.2 | 1.2 | 1.2 | 15.4 | 15.1 | 15.9 |
| HDFC (HDFC) | 2,496 | 3,100 | Buy | 4,503 | 59.8 | 75.6 | 87.7 | 41.7 | 33.0 | 28.5 | 4.1 | 3.9 | 3.8 | 2.0 | 2.3 | 2.3 | 11.1 | 12.3 | 13.5 |
| Bajaj Finserv (BAFINS) | 11,315 | 11,500 | Hold | 1,801 | 253.3 | 305.6 | 405.3 | 44.7 | 37.0 | 27.9 | 5.0 | 4.4 | 3.8 | 1.4 | 1.4 | 1.6 | 11.8 | 12.6 | 14.6 |
| Bajaj Finance (BAJFI) | 5,491 | 5,900 | Buy | 3,314 | 73.5 | 102.9 | 131.7 | 74.7 | 53.4 | 41.7 | 9.2 | 8.1 | 6.2 | 2.2 | 3.3 | 3.5 | 12.1 | 15.6 | 16.3 |
| Mahindra \& Mahindra Finance 154 |  | 160 Reduce |  | 190 | 2.7 | 7.2 | 10.4 | 56.6 | 21.5 | 14.8 | 1.7 | 1.4 | 1.2 | 0.4 | 1.2 | 1.6 | 2.6 | 5.7 | 7.3 |

Source: Company, IC/C/ Direct Research

## RATING RATIONALE

ICICI Direct endeavors to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15\%
Hold: -5\% to 15\%;
Reduce: -15\% to -5\%;
Sell: <-15\%


Pankaj Pandey
Head - Research
pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,
ICICl Securities Limited,
1st Floor, Akruti Trade Centre,
Road No 7, MIDC,
Andheri (East)
Mumbai - 400093
research@icicidirect.com

## ANALYST CERTIFICATION

I/We, Kajal Gandhi, CA, Vishal Narnolia, MBA and Sameer Sawant, MBA Research Analysts Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

## Terms \& conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products
CICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number - INH000000990. ICICI Securities Limited SEBI Registration is INZO00183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein

CICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

CICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

CICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own $1 \%$ or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.


[^0]:    Source: Company, IC/CI Direct Research

[^1]:    Source: Company, ICICI Direct Research

